Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice

Clin Investig Arterioscler. 2024 Jul-Aug;36(4):243-266. doi: 10.1016/j.arteri.2024.03.002. Epub 2024 Apr 9.
[Article in English, Spanish]

Abstract

The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment. Firstly, the measurement of Lp(a) is highly dependent on the test used, mainly because of the characteristics of the molecule. Secondly, Lp(a) concentration is more than 80% genetically determined, so that, unlike other cardiovascular risk factors, it cannot be regulated by lifestyle changes. Finally, although there are many promising clinical trials with specific drugs to reduce Lp(a), currently only iPCSK9 (limited for use because of its cost) significantly reduces Lp(a). However, and in line with other scientific societies, the SEA considers that, with the aim of increasing knowledge about the contribution of Lp(a) to cardiovascular risk, it is relevant to produce a document containing the current status of the subject, recommendations for the control of global cardiovascular risk in people with elevated Lp(a) and recommendations on the therapeutic approach to patients with elevated Lp(a).

Keywords: Clinical practice guideline; Guía de práctica clínica; Lipopotein(a); Lipopoteína (a); Lp(a).

Publication types

  • Review
  • Practice Guideline

MeSH terms

  • Arteriosclerosis
  • Atherosclerosis
  • Cardiovascular Diseases* / etiology
  • Cardiovascular Diseases* / prevention & control
  • Consensus
  • Heart Disease Risk Factors*
  • Humans
  • Lipoprotein(a)* / blood
  • PCSK9 Inhibitors
  • Spain

Substances

  • Lipoprotein(a)
  • PCSK9 Inhibitors